Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Aiforia provides advanced deep learning and cloud-based solutions to pathologists and researchers in both preclinical and clinical laboratories, enhancing their capabilities in image analysis and workflow efficiency. By enabling scientists to discover new disease biomarkers and assisting R&D professionals in accelerating the market introduction of innovative drugs, Aiforia plays a crucial role in improving cancer diagnostic accuracy while revolutionizing healthcare from the initial discovery phase through to diagnosis. For clinical pathology laboratories seeking to boost efficiency and elevate the precision of their diagnoses, the Aiforia Clinical Suites present a comprehensive range of AI-driven diagnostic tools, intelligent visualization, quality control, and automated pre- and post-screening functionalities. We are in the process of developing specialized Suites targeting some of the most common cancers globally and have achieved CE-IVD certification for our AI solutions in lung and breast cancer, positioning us as a leader in diagnostic innovation. Our commitment to enhancing patient outcomes through technology underscores the transformative potential of our offerings in the healthcare sector.
Description
By leveraging visual analytics through TIBCO Spotfire®, PerkinElmer Signals Translational offers a comprehensive suite of tools designed to harmonize, manage, search, aggregate, and analyze extensive datasets consistently for translational research, all while ensuring scalability. This platform, driven by TIBCO Spotfire®, supports precision medicine initiatives by providing an unparalleled solution for biomarker discovery and patient stratification. The Linear Mixed Effect App (LME) within Signals Translational empowers researchers to evaluate the influence of various factors on specific phenotypes, allowing for adjustments related to random variables during analysis. Furthermore, it enables the identification of genes significantly affecting cancer stage progression, irrespective of patient origins. Notably, the LME models excel at addressing issues such as missing values and outliers, making them a robust choice for discovering potential biomarkers. Consequently, the integration of these advanced analytics tools enhances the efficacy of translational research in identifying key biomarkers that can lead to more personalized treatment approaches.
API Access
Has API
No
API Access
Has API
No
Integrations
Charles River IMS
Yes
Microsoft 365
Yes
NVIDIA DRIVE
Yes
Signals Research Suite
No
Integrations
Charles River IMS
No
Microsoft 365
No
NVIDIA DRIVE
No
Signals Research Suite
Yes
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
No
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
Yes
Mac
Yes
Linux
No
Chromebook
No
Customer Support
Business Hours
Yes
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
Yes
Webinars
Yes
Live Training (Online)
Yes
In Person
Yes
Types of Training
Training Docs
Yes
Webinars
Yes
Live Training (Online)
Yes
In Person
No
Vendor Details
Company Name
Aiforia
Country
United States
Website
www.aiforia.com
Vendor Details
Company Name
PerkinElmer
Founded
1937
Country
United States
Website
perkinelmerinformatics.com/products/clinical-translational/signals-translational/